Unibest
← Back to patent-cliff list

CAS 1427038-62-7

(2-((tert-butoxycarbonyl)amino)ethyl)carbamic acid

Codes: PASI-029

Application context (from source-drug indications)

Cushing's syndromePasireotide DiaspartatePituitary ACTH hypersecretionPasireotide DiaspartatePost-bariatric hypoglycaemiaPasireotide DiaspartateCarcinoid tumourPasireotide DiaspartateNeuroendocrine tumourPasireotide DiaspartateCluster headachePasireotide Diaspartate

Source drugs (routes using this intermediate)

DrugTierExpiry
Pasireotide DiaspartateTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Pasireotide DiaspartateOptimised routesteps: 9total yield: /
(E)-prop-1-en-1-yl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-lysinate→PASI-025→PASI-026→PASI-027→PASI-028→(2-((tert-butoxycarbonyl)amino)ethyl)carbamic acid→PASI-030→PASI-031→PASI-032→PASI-033

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.